BeaconEquity.com announces the publication of “AVANT Immunotherapeutics (AVAN) Shares Surge 28% on Double Survival Rates from Vaccine Testin”
Investors can view all of the investment articles for free by visiting:
http://www.beaconequity.com/m - Click on News and Commentary
In the article the author covers AVANT Immunotherapeutics engages in the discovery, development and commercialization of vaccines and targeted immunotherapeutics:
”Cancer is a complex and sometimes fatal disease that creates pervasive adverse effects not only on the patients but on their families, friends and associates as well. According to the National Cancer Institute, approximately 19,000 people in the United States are diagnosed with primary brain cancers; the equivalent to a mortality rate of 15-to-20 deaths for every 100,000 people. Brain cancer accounts for 1.4 percent of all cancers, and 2.4 percent of all cancer deaths.
“AVANT Immunotherapeutics Inc. engages in the discovery, development and commercialization of vaccines and targeted immunotherapeutics for the treatment of cancer, infectious and inflammatory diseases.
“AVANT Immunotherapeutics shares surged 28 percent in yesterday's trading, after its partner, Pfizer Inc., released mid-stage data showing its CDX-110 vaccine doubled overall survival time and delayed disease progression…”
To read the entire article visit http://www.beaconequity.com/m – Click on News and Commentary
Join the fastest growing investor community at:
http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.beaconequity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
